CytomX Therapeutics Financial Results
CytomX Therapeutics reported Q3 2026 financial results and provided a business update, highlighting that its lead candidate Varsetatug masetecan (Varseta-M) received FDA Fast Track designation for metastatic colorectal cancer. The company expects to provide a Phase 1 monotherapy data update in January 2027 and potentially initiate its first registrational study in the first half of 2027.
“Varseta-M is a first-in-class EpCAM-directed antibody drug conjugate with a topoisomerase-1 inhibitor payload, intentionally designed to improve the standard of care for patients with colorectal and other cancers. At CytomX, we are highly focused on rapidly advancing monotherapy Varseta-M towards a first registrational study in colorectal cancer.”
Dr. Sean McCarthy, chairman and CEO of CytomX Therapeutics
“Additionally, the Varseta-M development program continues to broaden, including an ongoing combination study with bevacizumab in mCRC and the initiation of Phase 1 expansion cohorts in gastric and gastroesophageal junction cancer, EpCAM-selected pancreatic ductal adenocarcinoma, and EpCAM-selected biliary tract cancer. Our integrated strategy is intended to urgently advance Varseta-M for the maximum benefit of cancer patients.”
Dr. Sean McCarthy, chairman and CEO of CytomX Therapeutics